Sugi Predict

Sugi Predict / Compounds / SCHEMBL3618233

SCHEMBL3618233

SCHEMBL3618233

N[C@H](C(=O)O)c1cccc(Br)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 5/20 0.50
▸ TDP1 Q9NUW8 4/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ CYP2C9 P11712 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ CYP2C19 P33261 2/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ GRM8 O00222 1/20 0.50
▸ GRM6 O15303 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ SLC6A4 P31645 1/20 0.50
▸ DRD3 P35462 1/20 0.50
▸ GRM4 Q14833 1/20 0.50
▸ ALDH1A1 P00352 5/20 0.47
▸ KDM4E B2RXH2 4/20 0.47
▸ HPGD P15428 4/20 0.47
▸ GRM1 Q13255 3/20 0.47
▸ GRM2 Q14416 2/20 0.47
▸ IDO1 P14902 1/20 0.47
▸ TDO2 P48775 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30559593 1.00 HSD17B10 (0.50) HSD17B10TDP1MEN1CYP2C9KMT2A
SCHEMBL30559596 1.00 HSD17B10 (0.50) HSD17B10TDP1MEN1CYP2C9KMT2A
SCHEMBL2927725 1.00 HSD17B10 (0.50) HSD17B10TDP1MEN1CYP2C9KMT2A
Hydrochloric Acid SCHEMBL4212448 0.98 IDO1 (0.50) HSD17B10TDP1MEN1CYP2C9KMT2A
Methane SCHEMBL10697752 0.98 HSD17B10 (0.49) HSD17B10TDP1MEN1CYP2C9KMT2A
SCHEMBL21194008 0.86 L3MBTL1 (0.49) HPGDPARP1
SCHEMBL3649122 0.85 PARP1 (0.50) ALDH1A1HPGDIDO1TDO2PARP1
SCHEMBL11218425 0.83 PARP1 (0.44) ALDH1A1IDO1TDO2PARP1CTSA
SCHEMBL20930558 0.82 CYP2D6 (0.60) CYP2D6ALDH1A1IDO1TDO2PARP1
SCHEMBL30057779 0.81 MMP1 (0.48) HSD17B10TDP1MEN1CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR UNIV CALIFORNIA (US) 2026-03-26 — — US disclosed
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-12-02 — — US disclosed
US-12157778-B2 Peptides for activation of cell signaling in osteoprogenitor cells THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-03 — — US disclosed
US-20230346960-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-02 — — US disclosed
US-11612663-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-28 — — US disclosed
US-20220313867-A1 ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-10-06 — — US disclosed
WO-2018109496-A2 UNNATURAL AMINO ACIDS THE UNIVERSITY OF BRISTOL (GB) 2018-06-21 — — WO disclosed
EP-2114906-B1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS HOFFMANN LA ROCHE (CH) 2014-08-06 — — EP disclosed
US-8604061-B2 2-aminooxazolines as TAAR1 ligands HOFFMANN-LA ROCHE INC. (US) 2013-12-10 — — US disclosed
CN-101600700-B Novel 2-amino oxazolines as TAAR1 ligands for CNS disorders HOFFMANN LA ROCHE 2013-08-21 — — CN disclosed
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO (DE) 2012-08-02 — — US disclosed
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO 2010-05-13 — — US disclosed
EP-2114906-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. Hoffmann-Roche AG (CH) 2009-11-11 — — EP disclosed
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands F. HOFFMANN-LA ROCHE AG (CH) 2008-10-23 — — US disclosed
WO-2008092785-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R HSD17B10 1404/4885TDP1 767/4885MEN1 1746/4885
US-20230346960-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, PDGFRB, TEK HSD17B10 3339/4885TDP1 2245/4885MEN1 4811/4885
US-20220313867-A1 ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR FLT4, FLT1, KDR HSD17B10 2756/4885TDP1 2973/4885MEN1 2992/4885
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair PDGFA, PDGFRB, TEK HSD17B10 3339/4885TDP1 2245/4885MEN1 4811/4885
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R HSD17B10 1383/4885TDP1 957/4885MEN1 2373/4885
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, DCLRE1A, PDGFRA HSD17B10 4113/4885TDP1 883/4885MEN1 4697/4885
US-11612663-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair PDGFA, PDGFRB, TEK HSD17B10 3339/4885TDP1 2245/4885MEN1 4811/4885
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands TAAR1, TAAR5, NPY2R HSD17B10 1404/4885TDP1 767/4885MEN1 1746/4885
US-12157778-B2 Peptides for activation of cell signaling in osteoprogenitor cells ITGB4, ITGA4, ITGB1 HSD17B10 4210/4885TDP1 4865/4885MEN1 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.